Canntab Therapeutics Limited Stock Analysis
| CTABF Stock | USD 0.0001 0.00 0.00% |
Canntab Therapeutics Limited is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of Canntab Therapeutics pink sheet analysis is to determine its intrinsic value, which is an estimate of what Canntab Therapeutics Limited is worth, separate from its market price. There are two main types of Canntab Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Canntab Therapeutics pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Canntab Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Canntab |
Canntab Pink Sheet Analysis Notes
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.1. Canntab Therapeutics last dividend was issued on the 8th of March 2016. The entity had 1:200 split on the 20th of April 2018. Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. Canntab Therapeutics Limited is headquartered in Markham, Canada. Canntab Therapeutics is traded on OTC Exchange in the United States.The quote for Canntab Therapeutics Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Canntab Therapeutics Limited please contact Richard Goldstein at 289 301 3812 or go to https://canntab.ca.Canntab Therapeutics Investment Alerts
| Canntab Therapeutics generated a negative expected return over the last 90 days | |
| Canntab Therapeutics has some characteristics of a very speculative penny stock | |
| Canntab Therapeutics Limited has accumulated 126.2 K in total debt with debt to equity ratio (D/E) of 2.43, implying the company greatly relies on financing operations through barrowing. Canntab Therapeutics has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Canntab Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Canntab Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Canntab Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Canntab to invest in growth at high rates of return. When we think about Canntab Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 293.36 K. Net Loss for the year was (3.69 M) with loss before overhead, payroll, taxes, and interest of (939.01 K). | |
| Canntab Therapeutics Limited has accumulated about 691.11 K in cash with (2.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Canntab Therapeutics shares are held by company insiders |
Canntab Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 774.29 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Canntab Therapeutics's market, we take the total number of its shares issued and multiply it by Canntab Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
Canntab Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Canntab Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Canntab Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Canntab Therapeutics short-term fluctuations and highlight longer-term trends or cycles.
About Canntab Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Canntab Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Canntab shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Canntab Therapeutics. By using and applying Canntab Pink Sheet analysis, traders can create a robust methodology for identifying Canntab entry and exit points for their positions.
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. Canntab Therapeutics Limited is headquartered in Markham, Canada. Canntab Therapeutics is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Canntab Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Idea Breakdown Now
Idea BreakdownAnalyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
| All Next | Launch Module |
Complementary Tools for Canntab Pink Sheet analysis
When running Canntab Therapeutics' price analysis, check to measure Canntab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Canntab Therapeutics is operating at the current time. Most of Canntab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Canntab Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Canntab Therapeutics' price. Additionally, you may evaluate how the addition of Canntab Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |